Acute effects of Jägerbombs with energy drinks during a binge for healthy adults
Official title: Acute Effects of an Explosive Cocktail With Energy Drinks That is Trendy Among Young People, the Jägerbomb
Run by Fundació Institut Germans Trias i Pujol · NCT07588022 · Data updated 2026-11-12
This study tests whether mixing Jägermeister with an energy drink during a binge affects intoxication, mood, coordination, and sleepiness compared with alcohol alone in healthy adults who regularly drink caffeinated beverages.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Fundació Institut Germans Trias i Pujol Academic / other |
| Locations | 1 site (Barcelona) |
| Status | Recruiting |
| Started | February 18, 2026 |
| Main results expected | March 2027 |
| Study ends | June 2027 |
| Registry record updated | May 14, 2026 |
| Trial ID | NCT07588022 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-45 who regularly binge drink and have experience with caffeinated beverages, and who meet screening health criteria.
✕Probably not a fit
Individuals who do not engage in binge drinking or have contraindications to alcohol or caffeine may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, placebo-controlled trial compares the acute effects of a Jägerbomb versus alcohol alone in healthy adults with binge-drinking experience. Participants receive combinations of Jägermeister, energy drink, and their Placebos to isolate the specific effects of the energy drink as well as the mixed beverage. Outcomes include measures of psychomotor performance, perceived stimulation and reward, physiological stress markers, and reported hangover symptoms. The study uses a pilot phase with a predefined alcohol dose to establish tolerability and dosing parameters. Recruitment targets adults aged 18-45 with prior binge and caffeine-containing beverage experience, and will occur at Hospital Universitari Germans Trias i Pujol in Barcelona, Spain.
Why it matters
Potential benefit: If successful, the findings could clarify whether energy drinks alter the acute effects of alcohol during binge drinking.
How similar studies have gone: Previous research has explored energy drinks with alcohol and suggested linked behavioral and perception changes, but this exact combination has limited prior study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men and women between 18-45 years old with a weight between 50-90 kg for men and between 55-80 kg for women, and a body mass index (BMI) between 19-28 kg/m2. Lower or higher weights or BMIs are allowed, in the opinion of the Principal Investigator or the collaborators designated by the Principal Investigator and that do not pose a risk to the subjects and do not interfere with the objectives of the study. 2. Alcohol consumption in the form of occasional binge drinking (≥1 time/month), social alcohol consumption (≥10g/day distributed weekly) and experience in alcohol intoxication. 3. Consumption ≥7 drinks with methylxanthines (coffee, tea, chocolate, cola, BE) per week and who have consumed ED on at least one occasion. 4. Understand and agree to the trial procedures and sign an informed consent. 5. History and physical examination that demonstrate no organic or psychiatric disorders. 6. The ECG and general blood and urine tests performed before the test should be within normal limits. Minor or punctual variations from the limits of normality are allowed if, at the discretion of the Principal Investigator, taking into account the state of science, they are not of clinical significance, do not pose a risk to the subjects and do not interfere with the assessment of the product. These variations and their non-relevance will be justified in writing in a specific way. Exclusion Criteria: 1. Not meeting the inclusion criteria. 2. History or clinical evidence of gastrointestinal, liver, renal or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs. 3. Current history of substance use disorder according to DSM-V (except nicotine). A previous history of mild substance use disorder (corresponding to substance abuse according to DSM-IV criteria) is admitted. 4. History or clinical evidence of psychiatric disorders, alcoholism, abuse of drugs or other drugs or habitual consumption of psychoactive drugs. 5. Have participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks. 5\) Have suffered any organic disease or major surgery in the three months prior to the start of the study. 6\) Subjects who have an intolerance or have had serious adverse reactions to alcohol. The inclusion of subjects of oriental origin who do not have an intolerance to alcohol will be allowed. 7\) Have taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies, or dietary supplements that, in the judgment of the Principal Investigator or collaborators designated by the Principal Investigator, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to study sessions will not be grounds for exclusion if it is assumed to have been completely eliminated on the day of the experimental session. 8\) Smokers of \>5 cigarettes a day. 9) Consumption of more than 20 g of alcohol daily in women and more than 40 g in men. 10\) Consumers of more than 5 coffees, teas, colas, or other stimulant or xanthine beverages daily in the 3 months prior to the start of the study. 11\) Subjects who are not able to understand the nature of the trial and the procedures they are asked to follow. 12\) Subjects with positive serology for hepatitis B, C or HIV. 13) Women who are pregnant or breastfeeding, or who use hormonal contraceptives or do not use reliable contraceptive measures during the study (such as abstinence, intrauterine devices, barrier methods or with a vasectomized partner). 14\) Women with amenorrhea or premenstrual syndrome of severe intensity.
Where it's running
-
Hospital Universitari Germans Trias i Pujol-IGTP
Barcelona, Spain Recruiting
Study contacts
- Principal investigator: Clara Pérez Mañá, MD, PhD — Hospital Universitari Germans Trias i Pujol-IGTP
- Study coordinator: Clara Pérez-Mañá, MD, PhD
- Email: cperezm.mn.ics@gencat.cat
- Phone: +34934978865
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How age affects germinal center responses after flu and rabies vaccines
Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).
-
Magnetic field maps with NV sensors for non-invasive heart measurements
This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.
-
Methylation analyses using home-based self-sampling in women with and without gynecological disease
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.
-
Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products
This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.
-
A safe, carefully dosed test of TBD11 in healthy adults
This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.
-
Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm
This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.